- Home
- ACXP vs APRE Comparison
ACXP vs APRE Comparison
Compare ACXP & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- APRE
- Stock Information
- Founded
- ACXP 2017
- APRE 2006
- Country
- ACXP United States
- APRE United States
- Employees
- ACXP N/A
- APRE N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACXP Health Care
- APRE Health Care
- Exchange
- ACXP Nasdaq
- APRE Nasdaq
- Market Cap
- ACXP 8.4M
- APRE 10.0M
- IPO Year
- ACXP 2021
- APRE 2019
- Fundamental
- Price
- ACXP $0.47
- APRE $1.74
- Analyst Decision
- ACXP Strong Buy
- APRE Strong Buy
- Analyst Count
- ACXP 2
- APRE 2
- Target Price
- ACXP $10.00
- APRE $15.50
- AVG Volume (30 Days)
- ACXP 18.7M
- APRE 57.3K
- Earning Date
- ACXP 08-08-2025
- APRE 08-11-2025
- Dividend Yield
- ACXP N/A
- APRE N/A
- EPS Growth
- ACXP N/A
- APRE N/A
- EPS
- ACXP N/A
- APRE N/A
- Revenue
- ACXP N/A
- APRE $1,284,475.00
- Revenue This Year
- ACXP N/A
- APRE N/A
- Revenue Next Year
- ACXP N/A
- APRE N/A
- P/E Ratio
- ACXP N/A
- APRE N/A
- Revenue Growth
- ACXP N/A
- APRE 33.27
- 52 Week Low
- ACXP $0.30
- APRE $1.41
- 52 Week High
- ACXP $3.33
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- ACXP 52.38
- APRE 52.83
- Support Level
- ACXP $0.45
- APRE $1.70
- Resistance Level
- ACXP $0.59
- APRE $1.97
- Average True Range (ATR)
- ACXP 0.08
- APRE 0.17
- MACD
- ACXP -0.01
- APRE 0.01
- Stochastic Oscillator
- ACXP 27.06
- APRE 65.44
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.